12:00 AM
Jun 03, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Selumetinib: Phase II data

A double-blind, U.K. Phase II trial in 83 patients with wild-type BRAF advanced melanoma showed that twice-daily 75 mg oral selumetinib plus docetaxel non-significantly improved PFS (p=0.13), ORR (32% vs. 14%, p=0.059) and 6-month PFS rate...

Read the full 167 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >